KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer. PMID 38226931 · Urol Pract · 2024-Mar The study is a Phase II/III oncology trial with a drug intervention, but the report is a quality-of-life analysis of patient-reported outcomes. It does not contain the required primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier) for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of different regimens of short-term antibiotic prophylaxis in transrectal prostate biopsy. PMID 38219833 · J Hosp Infect · 2024-Mar The record is a randomized controlled trial in an oncology context (prostate cancer biopsy prophylaxis) with a drug intervention, but it is not a Phase III/IIIb or Phase II/III trial, and the primary endpoint (infectious complications) is not a time-to-event efficacy endpoint such as OS, PFS, DFS, etc. Therefore, it does not meet the inclusion criteria for a Phase III definitive RCT with a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of high-field iMRI guided resection in cerebral glioma surgery: A randomized clinical trial. PMID 38218157 · Eur J Cancer · 2024-Mar The study is a randomized trial in human oncology (brain neoplasms) with time-to-event endpoints (PFS, OS). However, it does not involve a drug-containing intervention (iMRI is a surgical/imaging technology) and does not explicitly establish Phase III/IIIb or Phase II/III evidence. Therefore, it fails the 'drug intervention' and 'phase3_or_definitive' criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial. PMID 38200233 · Br J Cancer · 2024-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Corrigendum to "Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score" [Eur. Urol. 83(5) (2024) 432-440]. PMID 38176992 · Eur Urol · 2024-Mar Record is a published erratum, not an original result report. While it references a randomized oncology trial with a time-to-event endpoint, the provided metadata does not explicitly confirm a drug intervention or definitive Phase III/IIIb status, and the report type is an erratum, not a primary result.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial. PMID 38174977 · Am J Hematol · 2024-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Transarterial Chemoembolization Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma (IDADOX): Protocol for a Randomized, Non-inferiority, Double-Blind Trial. PMID 38147153 · Cardiovasc Intervent Radiol · 2024-Mar 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial. PMID 38127215 · Ann Surg Oncol · 2024-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The impact of sex on treatment and outcome in relation to histological subtype in patients with resectable gastric cancer: Results from the randomized CRITICS trial. PMID 38073160 · J Surg Oncol · 2024-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Diversity in Oncology Clinical Trials: Current Landscape for Industry-Sponsored Clinical Trials in Asia. PMID 38064162 · Oncol Ther · 2024-Mar This is an observational study comparing characteristics of clinical trials, not a report of an individual randomized trial with efficacy results. It does not contain a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier or HR) for a specific drug intervention.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin's lymphoma: results from the randomized international GHSG HD18 trial. PMID 38061428 · Ann Oncol · 2024-Mar The study is a randomized oncology trial with drug intervention and time-to-event endpoints, but the primary endpoint is quality-of-life related (time to recovery from fatigue and time to return to work), not a formal efficacy endpoint like OS, PFS, DFS, EFS, RFS, or TTP. Therefore, it is excluded as a non-primary efficacy analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients. PMID 38060340 · Future Oncol · 2024-Mar The record is a published protocol (Phase IIb) for an ongoing trial. It does not report final or interim efficacy results, and the Phase IIb designation does not meet the Phase III/IIIb or Phase II/III definitive trial requirement. Therefore, it is excluded.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Robotic Management of Recurrent Rectal Endometriosis After Previous Segmental Bowel Resection. PMID 38043860 · J Minim Invasive Gynecol · 2024-Mar 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial. PMID 38016651 · Br J Haematol · 2024-Mar The record describes a randomized, oncology, human trial with a drug intervention and a time-to-event endpoint (OS). However, the trial phase is not explicitly established in the provided metadata or abstract, preventing confirmation of Phase III/IIIb or Phase II/III eligibility. Therefore, eligibility cannot be determined with the required certainty.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203. PMID 37996986 · Br J Haematol · 2024-Mar Oncology, human, randomized, drug intervention, and time-to-event endpoint are present. However, the trial phase (Phase III/IIIb or Phase II/III) is not explicitly stated in the provided metadata or abstract, so the 'phase3_or_definitive' criterion cannot be met. Therefore, the record is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Re: Pembrolizumab Versus Placebo as Post-nephrectomy Adjuvant Therapy for Clear Cell Renal Cell Carcinoma (KEYNOTE-564): 30-month Follow-up Analysis of a Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial. PMID 37957046 · Eur Urol · 2024-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA). PMID 37897617 · Eur J Nucl Med Mol Imaging · 2024-Mar The study is a randomized, controlled oncology trial with a drug intervention, but it is excluded because the primary efficacy endpoint is not a time-to-event outcome (e.g., survival or progression). It is a pharmacodynamic/biomarker endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Snare Tip Soft Coagulation vs Argon Plasma Coagulation vs No Margin Treatment After Large Nonpedunculated Colorectal Polyp Resection: a Randomized Trial. PMID 37871841 · Clin Gastroenterol Hepatol · 2024-Mar 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Effect of abdominal hot pack application on gastrointestinal motility recovery after comprehensive gynecologic staging surgery. PMID 37800343 · Int J Gynaecol Obstet · 2024-Mar The study is a randomized controlled trial with time-to-event endpoints in oncology patients. However, the intervention is non-drug (hot water pack), and the trial phase is not specified, failing the required criteria for drug intervention and phase classification.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical sonochemotherapy of inoperable pancreatic cancer using diagnostic ultrasound and microbubbles: a multicentre, open-label, randomised, controlled trial. PMID 37796294 · Eur Radiol · 2024-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor. PMID 37593881 · Future Oncol · 2024-Mar This is a phase III randomized trial protocol for an oncology drug intervention. However, the abstract does not report any results, efficacy data, or time-to-event endpoints (like OS, PFS, etc.) from a completed analysis; it only describes the trial design.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Effect of Magnesium Supplementation on Insulin Resistance and Metabolic Profiles in Women with Polycystic Ovary Syndrome: a Randomized Clinical Trial. PMID 37393389 · Biol Trace Elem Res · 2024-Mar 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. PMID 37387213 · Future Oncol · 2024-Mar This is a clinical trial protocol (publication type: Journal Article, Clinical Trial Protocol) for an ongoing Phase III study. It describes the study design but does not report any original results or efficacy data (no time-to-event endpoints such as OS, PFS, etc. are presented). The record is excluded as it is a protocol without results, not an original result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA. PMID 37271630 · Eur Urol · 2024-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin's lymphoma. PMID 37058173 · Eur J Health Econ · 2024-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: a secondary analysis of RTOG 0415. PMID 36849728 · Prostate Cancer Prostatic Dis · 2024-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Mediation Analysis of Obesity and Adiponectin Association with Postmenopausal Breast Cancer Risk: A Nested Cohort Study in the International Breast Cancer Intervention Study II (IBIS-II) Prevention Trial. PMID 38999846 · Nutrients · 2024-Jun-30 The record is a secondary biomarker/mediation analysis nested within the placebo arm of a randomized prevention trial. It does not report the efficacy results of a drug-containing intervention in the context of the trial's primary or key secondary endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. PMID 38989411 · J Gastrointest Oncol · 2024-Jun-30 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Effects of Dietary Intervention and Macrophage-Activating Factor Supplementation on Cognitive Function in Elderly Users of Outpatient Rehabilitation. PMID 38999825 · Nutrients · 2024-Jun-28 The study is not an oncology trial. It investigates dietary intervention and macrophage-activating factor supplementation for cognitive function in elderly rehabilitation patients, with exclusion criteria including terminal cancer, and does not report a primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) for a malignant neoplasm. It also does not involve a drug intervention as defined for oncology trials.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia-a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial. PMID 38943201 · Trials · 2024-Jun-28 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Hydromorphone combined with ropivacaine for erector spinae plane block in patients undergoing modified radical mastectomy: A prospective randomized controlled trial. PMID 38941366 · Medicine (Baltimore) · 2024-Jun-28 The study is a randomized controlled trial in breast cancer patients, but it does not meet the core criteria: the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the primary endpoints are postoperative analgesic efficacy and recovery (e.g., pain scores, IL-6, anal exhaust time), not time-to-event oncology efficacy outcomes like OS or PFS. The drug intervention (hydromorphone/ropivacaine) is for analgesia during anesthesia, not a systemic anticancer drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Study Protocol of a Randomized, Two-Arm, Phase I/II Trial Investigating the Feasibility, Safety, and Efficacy of Local Treatment with US-Guided High-Intensity Focused Ultrasound in Combination with Palliative Chemotherapy in Inoperable Pancreatic Cancer. PMID 38999283 · J Clin Med · 2024-Jun-26 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Scalable Telehealth Cancer Care: integrated healthy lifestyle program to live well after cancer treatment. PMID 38924795 · J Natl Cancer Inst Monogr · 2024-Jun-26 This is a randomized, pragmatic clinical trial in cancer survivors evaluating a telehealth-delivered lifestyle intervention versus usual care. The outcomes are reach, effectiveness, and cost, with no mention of time-to-event efficacy endpoints like OS, PFS, DFS, or Kaplan-Meier/HR analyses. Additionally, the intervention is a behavioral/lifestyle program, not a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101. PMID 38598710 · Blood Adv · 2024-Jun-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Pioneering the implementation of a precision oncology strategy in Portugal: the Precision Oncology Platform trial. PMID 38910310 · Acta Oncol · 2024-Jun-23 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. PMID 38843860 · Lancet · 2024-Jun-22 The study meets criteria for being an original, randomized, Phase 3, oncology, human trial with a drug intervention. However, it is excluded because its primary efficacy endpoint is objective response rate, not a time-to-event endpoint (like OS, PFS, etc.), and there is no signal of a key secondary time-to-event endpoint in the provided abstract.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial. PMID 38906541 · BMJ · 2024-Jun-21 Cannot confirm a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR) from the provided metadata (abstract is empty, no publication_types for results, no keywords/MESH indicating endpoints). The title suggests a clinical trial report, but without explicit endpoint information, eligibility is indeterminate.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
BOLERO-5: a phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER + /HER2- advanced breast cancer. PMID 38904918 · Discov Oncol · 2024-Jun-21 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer. PMID 38902698 · Respir Res · 2024-Jun-21 The record is an original analysis using data from a randomized trial, but it is a post-hoc biomarker-focused subgroup analysis (report_type: 'subgroup'), not the primary report of the overall trial results. Therefore, it does not meet the criterion for being an 'original formal-result report' of the definitive randomized comparison.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. PMID 39516558 · BJC Rep · 2024-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design. PMID 38902836 · Trials · 2024-Jun-20 This is a protocol for a randomized controlled trial (RCT) assessing postoperative surveillance. It is not an original report of trial results. While the trial is oncology, human, and randomized with a time-to-event endpoint, the protocol does not provide results and does not explicitly establish a drug-containing intervention (the intervention is surveillance, not a specific drug regimen).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. PMID 38537155 · J Clin Oncol · 2024-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The effect of educational intervention based on health belief model on colorectal cancer screening behaviors. PMID 38898503 · BMC Public Health · 2024-Jun-19 The study is an oncology-focused randomized trial with original results, but it is a quasi-experimental educational intervention study without a drug-containing intervention and does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study. PMID 38886794 · BMC Med · 2024-Jun-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US. PMID 38886516 · Sci Rep · 2024-Jun-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy. PMID 38447003 · Int J Cancer · 2024-Jun-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance. PMID 38353455 · Cancer · 2024-Jun-15 The study is a randomized controlled trial in oncology (prostate cancer) but is not a Phase III/IIIb or Phase II/III trial of a drug-containing intervention, and the primary endpoint is change in glucose regulation biomarkers, not a time-to-event efficacy endpoint (OS, PFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Use of an emulated trial to investigate the association between use of nitrogen-based bisphosphonates and risk of epithelial ovarian cancer. PMID 39133937 · Int J Epidemiol · 2024-Jun-12 The record describes an observational epidemiological study that emulates a trial, not a randomized controlled trial. It lacks a formal clinical trial phase (Phase III/IIIb or Phase II/III). While it involves oncology, humans, a drug intervention, and time-to-event endpoints, the absence of randomization and definitive trial phase makes it ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical features of audible upper airway secretions ("death rattle") in patients with cancer in the last days of life. PMID 38862857 · Support Care Cancer · 2024-Jun-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries. PMID 38928138 · Int J Mol Sci · 2024-Jun-11 The record reports final results from a randomized Phase III/IIIb trial (HOVON-65/GMMG-HD4) in multiple myeloma with drug-containing interventions and primary time-to-event efficacy endpoints (PFS, OS). All required criteria are explicitly met in the abstract.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 4 Panel · risk visible